Merck KGaA

Merck KGaA

MRK.DE

€133.15

Updated: 23/09/2026, 04:10:49

Market Cap
€57.85B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
DE
Stock valuation chart
One-year closing share-price history for MRK.DE
Company Profile

Merck KGaA is a German science and technology company with operations divided into three core segments: Life Science, Healthcare, and Electronics. The Life Science division supplies essential tools, chemicals, and equipment to academic research institutions, biotechnology firms, pharmaceutical manufacturers, and various industrial sectors. It also offers specialized process development expertise, such as continuous bioprocessing for drug manufacturers, provides a range of testing kits, reagents, and services, and develops solutions for analyzing environmental samples like air, water, and soil. Furthermore, this segment aids in assessing nutritional value and identifying quality control issues. In its Healthcare segment, the company is involved in the entire lifecycle of prescription drugs and biopharmaceuticals, from initial discovery and development through manufacturing and marketing. Its therapeutic focus areas include oncology, neurology and immunology, fertility, endocrinology, cardiovascular diseases, diabetes, thyroid disorders, and multiple sclerosis. This segment also produces general medicines, injection devices, and software for disease monitoring. The Electronics division delivers critical materials for the semiconductor and display industries. It also specializes in surface design, providing delivery systems and services, along with a variety of surface solutions for applications such as cosmetics, effect pigments, and other functional materials. Merck KGaA is also actively engaged in strategic partnerships. These include in-licensing agreements with Debiopharm International SA for developing treatments for head and neck cancer, with Jiangsu Hengrui Pharmaceuticals Co. Ltd. for metastatic colorectal cancer drug candidates, and with Abbisko Therapeutics Co. Ltd. for therapies targeting tenosynovial giant cell tumors. Additionally, the company is involved in collaborations focused on discovering and developing targeted protein degraders against critical oncogenic proteins. Founded in 1668 and headquartered in Darmstadt, Germany, Merck KGaA operates as a subsidiary of E. Merck KG.

EUR
XETRA
CEO: Kai Beckmann
Employees: 62,136
https://www.emdgroup.com
Asset Summaries
Latest generated summaries for MRK.DE

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for MRK.DE.
Share price
€133.15
Market cap
€57.85B
Exchange
XETRA
Currency
EUR
CEO
Kai Beckmann
Employees
62,136
IPO date
26/06/1998
Beta
0.805
Last dividend
€0.00
Day range
€132.10 – €134.00
52-week range
€100.70 – €148.80
1-day performance
0.41%
1-year performance
32.22%
Current drawdown (1Y)
-10.52%
CIK
N/A
CUSIP
D5357W103
ISIN
DE0006599905
Created
07/09/2026, 05:15:42
Last update
23/09/2026, 04:10:49

Track Merck KGaA with an AI analyst

See which prediction-market events move MRK.DE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to MRK.DE from your Railway `news_articles` table.

No news found for this symbol.